Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Keros Therapeutics' Operating Expenses history spans 7 years, with the latest figure at $29.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 47.32% year-over-year to $29.7 million; the TTM value through Dec 2025 reached $176.5 million, down 17.67%, while the annual FY2025 figure was $176.5 million, 17.67% down from the prior year.
  • Operating Expenses reached $29.7 million in Q4 2025 per KROS's latest filing, roughly flat from $29.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $59.2 million in Q1 2025 to a low of $15.6 million in Q2 2021.
  • Average Operating Expenses over 5 years is $37.6 million, with a median of $35.4 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 96.46% in 2022, then crashed 49.79% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $24.9 million in 2021, then grew by 28.53% to $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then grew by 20.81% to $56.3 million in 2024, then crashed by 47.32% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Operating Expenses are $29.7 million (Q4 2025), $29.6 million (Q3 2025), and $58.0 million (Q2 2025).